What's the Next Stop? Barron's A number of its product candidates tackle autoimmune disorders, including rheumatoid arthritis and transplant rejection. Antoian says Maxygen has $5.77 a share in cash, yet the shares have been trading for just $6.00. He believes it's worth $7.50. ... |
